|

REGN15505+REGN4336 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Regeneron Pharmaceuticals1

Indications

  • Clear Cell Renal Cell Carcinoma (ccRCC)1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1
  • Cancer1

Goodyear, Arizona1 trial

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

City of Hope Phoenix

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.